Edwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
Follow EW
Edwards Lifesciences Corporation (EW) Return on invested capital
Edwards Lifesciences Corporation's return on invested capital over the twelve months to 30 June 2026 was 12.8%, up 1.0 percentage points from fiscal 2025 (11.8%). Over the past ten years it has ranged from 11.8% (fiscal 2025) to 25.6% (fiscal 2017) — the current reading is the lowest in ten years. That is above the Medical Devices industry median of −10.3% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 11.8% | (1.11) |
| FY2024 | 12.9% | (1.50) |
| FY2023 | 14.4% | (3.66) |
| FY2022 | 18.1% | (3.23) |
| FY2021 | 21.3% | 6.39 |
| FY2020 | 14.9% | (7.33) |
| FY2019 | 22.2% | 5.39 |
| FY2018 | 16.8% | (8.81) |
| FY2017 | 25.6% | 3.07 |
| FY2016 | 22.6% | 1.15 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| DXCM DexCom, Inc. compare | 37.1% |
| EW Edwards Lifesciences Corporation | 12.8% |
| SYK Stryker Corporation compare | 9.76% |
| GEHC GE HealthCare Technologies Inc. compare | 8.37% |
| STE STERIS plc compare | 8.27% |
| BSX Boston Scientific Corporation compare | 6.96% |
| PHG Koninklijke Philips N.V. compare | 6.69% |
| MDT Medtronic PLC compare | 6.04% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.82% |
| Medical Devices industry median | −10.3% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on EW
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement